Open AccessGraves’ Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature
Author(s) -
Alessandro Brancatella,
Nicola Viola,
Sandra Brogioni,
Lucia Montanelli,
Chiara Sardella,
Paolo Vitti,
Claudio Marcocci,
Isabella Lupi,
Francesco Latrofa
Publication year - 2019
Publication title -
european thyroid journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.23
H-Index - 10
eISSN - 2235-0802
pISSN - 2235-0640
DOI - 10.1159/000501824
Subject(s) - medicine , trab , nivolumab , graves' disease , thyroiditis , autoantibody , ipilimumab , thyroid cancer , thyroid , disease , autoimmune thyroiditis , anti thyroid autoantibodies , immunotherapy , immunology , cancer , antibody
In the last few years, immune checkpoint inhibitors (ICPis) have become a common treatment of cancer. ICPis are associated with peculiar immune side effects, termed immune-related adverse events (irAEs). Thyroid disfunction is a common irAE, but clinical manifestation, severity, and pathogenesis can be variable. While destructive thyroiditis and hypothyroidism are the most common thyroid irAEs induced by ICPis, autoimmune hyperthyroidism (Graves' disease) is rare. We describe a case of a Graves' disease induced by anti-PD-1 therapy and we review the previous reports on this issue.